Saturday, June 22, 2013 10:37:03 PM
Now what effect does this have on number of shares and value? Originally the proposal was to issue 4,859,894 warrants executable at $4.80. Since it did not pass, the following rule applies;
In the event DSS’s stockholders approve the issuance of the merger consideration, but do not approve the authorization of the DSS Preferred Stock, then the holders of Lexington Preferred Stock that satisfy the Beneficial Ownership Condition shall receive warrants to purchase DSS Common Stock with an exercise price of $0.02 per share, which we refer to as the $.02 Warrants. Each $.02 Warrant is exercisable at any time after the date of issuance for a period of ten years. If at any time between the three month anniversary of the issuance date and the expiration date, there is no effective registration statement registering the resale of the shares issuable under the Warrants, then the holder may elect to exercise the Warrants, or a portion thereof, by way of a cashless exercise. Except under certain circumstances, no holder may exercise its Warrants or $.02 Warrants if such exercise would result in such holder beneficially owning in excess of 9.99% of the number of shares of DSS common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise of the Warrants. In addition, under certain circumstances, a holder of the $.02 Warrants will be entitled to participate in any distribution of DSS’s assets (or the right to acquire its assets) or any declared cash dividend, to the same extent such holder would have participated therein if such holder had held the shares of common stock acquirable upon complete exercise of the $.02 Warrants.
Vet away....
Recent DSS News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:15:31 PM
- Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition." • GlobeNewswire Inc. • 01/30/2024 01:05:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:54:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:05:40 PM
- DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market • GlobeNewswire Inc. • 01/04/2024 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:15:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:10:36 PM
- DSS, Inc. Announces Reverse Split as Part of NYSE American Compliance Plan • GlobeNewswire Inc. • 12/22/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:30:23 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 12/13/2023 09:15:25 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/01/2023 09:15:06 PM
- Premier Packaging, a Wholly-Owned Subsidiary of DSS, Inc., Secures Contract Extension with Major Retailer Worth Up to $15 Million over Four Years • GlobeNewswire Inc. • 11/28/2023 01:10:00 PM
- DSS Inc. Wins Patent Dispute with Nichia Corporation • GlobeNewswire Inc. • 11/14/2023 01:00:00 PM
- DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Reverse Split of Outstanding and Issued Common Stock and Conversion of Certain Holder’s Common Stock • GlobeNewswire Inc. • 11/08/2023 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 09:25:10 PM
- DSS Inc. Receives Notice of Non-Compliance with NYSE American Trading Share Price Listing Rule • GlobeNewswire Inc. • 10/26/2023 09:25:00 PM
- DSS, Inc. Announces Filing of Registration Statement on Form S-1 for Initial Public Offering of Impact Biomedical • GlobeNewswire Inc. • 10/23/2023 12:25:00 PM
- DSS Inc. Issues Letter to Shareholders • GlobeNewswire Inc. • 10/12/2023 12:25:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 08:31:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:30:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/12/2023 08:30:20 PM
- DSS Inc. Expands DSS Wealth Management, Inc.'s Management Team for Ramp Up of Asset Management Subsidiary • GlobeNewswire Inc. • 09/06/2023 12:40:00 PM
- DSS Inc. Announces Distribution Date of August 8, 2023 for Spinoff of Impact BioMedical Inc. • GlobeNewswire Inc. • 07/31/2023 12:15:00 PM
- DSS Inc. Appoints Daniel Lew as Chief Investment Officer and Portfolio Manager for DSS Wealth, Inc. • GlobeNewswire Inc. • 07/05/2023 12:15:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM